Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-12 with LGG in Autism Spectrum Disorder
NCT03514784Phase 2Completed
- Sponsor
- UTHealth Houston
- Start
- May 2016
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BB-12 + LGG in Autism Spectrum Disorder (ASD) (3 arms), sponsored by UTHealth Houston. Primary endpoints: Number of Participants With Invasive Infection Resulting From the Administration of Probiotic at 56 days, Number of Participants With Clinical Tolerance of the Probiotic at 56 days and 1 more. Started May 2016; status: completed.
02
Drugs
BB-12 + LGG
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03514784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514784.